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A combination of phenotypic and genotypic methods was used to investigate 70 unique Escherichia coli
clinical isolates identified as producing extended-spectrum -lactamases (ESBLs) at a medical center in
Pittsburgh, PA, between 2007 and 2008. Fifty-seven isolates (81%) produced CTX-M-type ESBLs, among which
CTX-M-15 was predominant (n  46). Isolates producing CTX-M-2, -9, -14, and -65 were also identified. One
CTX-M-producing isolate coproduced CMY-2 cephalosporinase. Ten isolates (14%) produced SHV-type
ESBLs, either SHV-5 or SHV-7. Two isolates produced only CMY-2 or -32. Pulsed-field gel electrophoresis revealed
the presence of two major clusters of CTX-M-15-producing E. coli isolates, one in phylotype B2 (n  15) and
the other in phylotype A (n  19). Of four phylotype B2 isolates that were able to transfer the blaCTX-M-15-
carrying plasmids, three showed fingerprints related (>60%) to those of plasmids from phylotype A isolates.
In phylotype B2, all CTX-M-15-producing isolates, as well as three isolates producing CTX-M-14, two pro-
ducing SHV-5, and one producing SHV-7, belonged to the international epidemic clone defined by serotype
O25:H4 and sequence type 131. The plasmids from eight of nine CTX-M-15-producing E. coli isolates of
phylotype A that were examined were highly related to each other and were also found in two isolates belonging
to phylotype D, suggesting horizontal transfer of this blaCTX-M-15-carrying plasmid between phylotypes. Our
findings underscore the need to further investigate the epidemiology and virulence of CTX-M-producing E. coli
in the United States.
The most common cause of resistance to expanded-spec-
trum cephalosporins in Escherichia coli is the production of
extended-spectrum -lactamases (ESBLs) (29). In the past de-
cade, CTX-M-type ESBLs have replaced TEM- and SHV-type
ESBLs in Europe, Canada, and Asia as the most common
ESBL type in this species (1, 4, 19, 22, 25, 30). The United
States initially appeared immune to this epidemic of CTX-M-
type ESBLs. However, an increasing number of reports now
indicate that CTX-M-type ESBLs have emerged in E. coli and
other species of Enterobacteriaceae in the United States as well
(7, 17, 24). A study performed in Texas revealed that CTX-M-
producing E. coli strains were already present in small numbers
in 2000 and became predominant by 2004 (22).
CTX-M-type ESBLs can be grouped into five clusters ac-
cording to genetic relatedness: the CTX-M-1, -2, -8, -9, and -25
groups (5a). Of the different CTX-M-type ESBLs, CTX-M-15,
which belongs to the CTX-M-1 group, is now the most widely
distributed enzyme worldwide. CTX-M-15 was first identified
in an isolate from India in 1999 (18) and then became preva-
lent worldwide (5, 6, 11, 23). CTX-M-15 differs from CTX-M-3
by one amino acid substitution at position 240 (Asp240Gly).
This substitution enhances hydrolytic activity against ceftazi-
dime, which otherwise is not a preferred substrate for CTX-
M-type ESBLs (31). Of note, a particular clone of CTX-M-15-
producing E. coli, characterized by phylogenetic type
(phylotype) B2, serotype O25:H4, and sequence type 131
(ST131), appears to be responsible for a large part of the
international epidemic of CTX-M-producing E. coli (11, 27).
Here we describe detailed molecular-epidemiology and plas-
mid analyses of CTX-M-producing E. coli isolates identified at
our medical center in Western Pennsylvania.
MATERIALS AND METHODS
Bacterial strains. A total of 70 consecutive and unique E. coli isolates iden-
tified from patient specimens between May 2007 and April 2008 at the clinical
microbiology laboratory of the University of Pittsburgh Medical Center were
included. These isolates had positive phenotypic confirmatory test results for
ESBL production based on 5-mm increases in zone diameters when a ceftazi-
dime or cefotaxime disk was combined with clavulanic acid, as described in the
Clinical and Laboratory Standards Institute (CLSI) guidelines (10). The sources
of isolates and patient locations were recorded, and the isolates were kept at
80°C until use.
Susceptibility testing. The antimicrobial susceptibilities of the study strains to
ceftazidime, ceftazidime–clavulanic acid, cefotaxime, cefotaxime–clavulanic acid,
cefoxitin, cefepime, imipenem, ciprofloxacin, gentamicin, tetracycline, chloram-
phenicol, sulfamethoxazole–trimethoprim, and amikacin were determined by
using the disk diffusion assay as defined by the CLSI (10). ESBL production was
phenotypically reconfirmed by using the same disk method in the research
laboratory.
PCR analysis and nucleotide sequencing. (i) PCR for detection of resistance
genes and determination of phylotypes. Crude genomic DNA was extracted from
the isolates by heat lysis. The DNA was then subjected to PCR using specific
primer pairs to screen for -lactamase genes (consensus blaCTX-M, blaCTX-M-2,
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blaCTX-M-9, blaCTX-M-15, blaSHV, blaTEM, blaCMY, and blaOXA-1) (2, 12, 14, 26,
34, 35) and phylotypes (Table 1) (8). PCR analysis was performed using a
GeneAmp thermal cycler, model 9700 (Applied Biosystems, Foster City, CA).
DNA sequencing of resistance genes was performed using an ABI 3730 instru-
ment with primers that generated the amplified products. Sequences were then
analyzed using the BLAST software available from the National Library of
Medicine (http://www.ncbi.nlm.nih.gov/blast).
(ii) O25 typing, plasmid incompatibility grouping, and MLST. PCR-based
O25 typing was employed for all E. coli isolates using the primers listed in Table
1. Ten CTX-M-15-producing E. coli isolates were O and H typed at the E. coli
Reference Center, Pennsylvania State University. Further, to identify the pan-
demic clone characterized by serotype O25:H4, STs were determined by mul-
tilocus sequence typing (MLST) for O25 PCR-positive isolates as well as for
CTX-M-15-producing E. coli isolates belonging to phylotypes D (n  2) and A
(n 5) (37). PCR products from MLST were also sequenced as described above.
Allelic profiling and ST determinations were performed through the E. coli
MLST website maintained at the Max-Planck Institut fuer Infektionsbiologie
(now at the ERI, University College Cork [http://mlst.ucc.ie/mlst/dbs/Ecoli]).
PFGE. All isolates were evaluated for genomic clonality by pulsed-field gel
electrophoresis (PFGE). Genomic DNAs of 70 isolates were prepared as de-
scribed previously (32). Fingerprints were generated by restriction endonuclease
XbaI (New England Biolabs, Ipswich, MA) and subjected to electrophoresis
using a CHEF-DR III system (Bio-Rad, Hercules, CA) at 6 V with pulse times
of 2.2 to 54.2 s and linear ramping at 14°C for 22 h. A lambda ladder (New
England Biolabs) was used as the DNA size marker. The relatedness of PFGE
patterns was determined by the unweighted-pair group method using average
linkages and cluster analysis with the Dice setting on Bionumerics software,
version 4.0 (Applied Maths, Sint-Martens-Latem, Belgium).
Plasmid extraction, transfer, and Southern hybridization. Plasmids of 16
isolates carrying blaCTX-M-15 were analyzed in detail, as described below, in order
to compare them within the collection and also with blaCTX-M-15-carrying plas-
mids characterized in non-U.S. isolates. In addition, four isolates producing
blaCTX-M-2, blaCTX-M-14, or blaCTX-M-65 were also included in order to compare
the relatedness among the plasmids. The transferability of blaCTX-M-15-carrying
plasmids was assayed by both transformation and conjugation. The transferabil-
ity of plasmids by conjugation was analyzed by liquid mating in Luria-Bertani
(LB) broth with the sodium azide-resistant E. coli strain J53AziR as the recipient.
Transconjugants were selected on LB agar containing sodium azide at 100 g/ml
and ampicillin at 50 g/ml. The transfer of a blaCTX-M-carrying plasmid was
confirmed by the resistance profiles of the transconjugants and positive PCR
results for blaCTX-M. For the examination of plasmid transferability by transfor-
mation and for use in fingerprinting, plasmids were extracted using the alkaline
lysis method and were transformed into E. coli DH10B by electroporation as
previously described (35). Transformants were selected on LB agar containing 2
g/ml of cefotaxime (Sigma-Aldrich, St. Louis, MO). The fingerprints of the
blaCTX-M-carrying plasmids were generated by digesting plasmids with restriction
enzyme HpaI (New England Biolabs). After electrophoresis, plasmid fingerprints
were visualized and then transferred to a positively charged nylon membrane
(Roche Diagnostics, Indianapolis, IN). DNA probes were prepared from PCR
amplicons of blaCTX-M-15 using a digoxigenin nucleic acid labeling and detection
system (Roche Diagnostics). The clonality of the plasmid fingerprints was
assessed using Bionumerics software. The presence of blaTEM, blaOXA-1, and
aac-(6)-Ib on these plasmids was determined as well. The plasmid profiles
were compared to the published characteristics of blaCTX-M-15-carrying plas-
mids (5, 11).
RESULTS
Antimicrobial susceptibilities of E. coli isolates. The sources
of the 70 study isolates included urine (48 isolates), superficial
wounds (9 isolates), bronchoalveolar lavage fluid (7 isolates),
sputum (3 isolates), and blood (3 isolates). No cluster of cases
according to patient location was observed. Two isolates
showed a phenotype consistent with AmpC production and
only minimal inhibition by clavulanic acid. They did not carry
ESBL genes but instead carried CMY-type cephalosporinase
genes. The remaining 68 ESBL producers were resistant to
cefotaxime or ceftazidime or to both and showed inhibition by
clavulanic acid (zone diameter increase of 5 mm with com-
bination disks containing ceftazidime or cefotaxime plus cla-
vulanic acid compared with disks containing ceftazidime or
cefotaxime alone). All but six isolates were resistant to cipro-
floxacin (92%). All isolates in this study were susceptible to
imipenem.
Resistance genes and phylotypes. Table 2 shows the distri-
bution of ESBL and CMY-type cephalosporinase genes and
phylotypes. CTX-M was the predominant ESBL type, pro-
duced by 81% of all isolates (n  57). All isolates carrying
blaCTX-M showed resistance to cefotaxime. Additionally, 46
CTX-M-producing E. coli isolates were also resistant or inter-
mediately resistant to ceftazidime. These 46 isolates carried
blaCTX-M-15. The other CTX-M-type ESBL genes identified
were in the blaCTX-M-2 and blaCTX-M-9 groups (Table 2). The
TABLE 1. Primers used for amplification of resistance genes and replicon typing
Primer Target gene/site Sequence (5 to 3) Annealingtemp (°C) Reference
TEMF blaTEM ATGAGTATTCAACATTTCCGTG 55 12
TEMR TTACCAATGCTTAATCAGTGAG
SHV S1 blaSHV ATTTGTCGCTTCTTTACTCGC 55 12
SHV S2 TTTATGGCGTTACCTTTGACC
CTX-M/F blaCTX-M TTTGCGATGTGCAGTACCAGTAA 51 14
CTX-M/R CGATATCGTTGGTGGTGCCATA
CTX-M-2 group F blaCTX-M-2 AAATGTGCTGCTCCTTTCGTGAGC 60 12
CTX-M-2 group R AGGGTTCGTTGCAAGACAAGACTG
CTX-M-9 group F blaCTX-M-9 GTGACAAAGAGAGTGCAACGC 60 34
CTX-M-9 group R ATGATTCTCGCCGCTGAAGCC
CTX-M-15-SF blaCTX-M-15 CACACGTGGAATTTAGGGACT 55 26
CTX-M-15-SR GCCGTCTAAGGCGATAAACA
CMY-F blaCMY CCGGACACCTTTTTGCTTTT 60 35
CMY-R TATCCTGGGCCTCATCGTCAGTTA
OXA-1 F blaOXA-1 TTTTCTGTTTGGGTTTT 52 2
OXA-2 R TTTCTTGGCTTTTGTGCTTG
aac(6)-1b f aac(6)-Ib TTGCGATGCTCTATGAGTGGCTA 55 28
aac(6)-1b r CTCGAATGCCTGGCGTGTTT
rfb.1bis O typing for O25 ATACCGACGACGCCGATCTG 60 9
rfb25.r TGCTATTCATTATGCGCAGC
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majority of the 10 isolates in the blaCTX-M-9 group possessed
blaCTX-M-14 (n  8). A single isolate possessed both blaCTX-M-65
(blaCTX-M-9 group) and blaCMY-2, which were carried on two
separate transferable plasmids. SHV-producing E. coli isolates
were detected less frequently (n  10 [14%]). These isolates
carried blaSHV-5 or blaSHV-7 and were resistant to ceftazidime
and intermediately resistant to cefotaxime. The two isolates
possessing blaCMY-2 or blaCMY-32 but no ESBL gene were
considered false-positive ESBL producers. This rare phenom-
enon has been reported previously for some isolates possessing
plasmid-mediated cephalosporinase (33, 35). Only a single iso-
late had a TEM-type ESBL gene, which was identified as
blaTEM-10. This isolate was resistant to ceftazidime and had
reduced susceptibility to cefotaxime. The blaTEM-10-carrying
plasmid was also transferable, and the transformant showed
the same resistance profile as the parent isolate.
Overall, there was no predominance of a particular phylo-
type in this study. A total of 27, 1, 24, and 18 isolates belonged
to phylotypes A, B1, B2, and D, respectively (Table 2). Of the
24 isolates in phylotype B2, 15 produced CTX-M-15. Most of
the phylotype A isolates (25 of 27) were CTX-M-15 producers
as well. ESBLs produced by phylotype D isolates were more
variable (Table 2).
O25 typing and MLST. Twenty-one isolates belonging to
phylotype B2 (15 producing CTX-M-15, 3 producing CTX-M-
14, 2 producing SHV-5, and 1 producing SHV-7) were deter-
mined to be serotype O25:H4 and ST131. All six CTX-M-15-
producing E. coli isolates belonging to phylotype A that were
tested for ST had ST410, which belongs to the ST23 complex.
These strains were found to have serotype O20:H9. The two
CTX-M-15-producing E. coli isolates belonging to phylotype D
were nonserotypeable and were determined to be ST648.
Molecular typing for clonal detection. DNA fingerprints re-
sulting from PFGE were assigned to pulsotypes. Each pulso-
type comprised genetically related or indistinguishable isolates.
PFGE revealed the presence of two predominant pulsotypes,
designated pulsotype A (n  19), with 75% similarities, and
pulsotype B (n  18), with 50% similarities (Fig. 1). All 19
isolates in pulsotype A had phylotype A and produced CTX-
M-15. All 15 CTX-M-15-producing isolates in pulsotype B had
phylotype B2. Additionally, three phylotype B2 isolates pro-
ducing CTX-M-14 and three producing SHV (two SHV-5 iso-
lates and one SHV-7 isolate) belonged to pulsotype B. The rest
of the isolates (including 12 CTX-M-15 producers) were
clonally diverse, with each pulsotype containing three isolates
or fewer.
Plasmid analysis. The antimicrobial resistance genes
blaOXA-1 and aac-(6)-Ib were consistently present on the
blaCTX-M-15-carrying plasmids of all phylotype A isolates
tested. Unlike the international epidemic clone, however, our
blaCTX-M-15-carrying plasmids in this clonal group did not pos-
sess blaTEM (5, 11). For CTX-M-15-producing E. coli isolates
in phylotype B2, after multiple attempts at conjugation and
transformation from all parent strains, plasmids from only four
isolates were transferable by conjugation or transformation.
The other antimicrobial resistance genes located on this
blaCTX-M-15-carrying plasmid were variable, with plasmids
from two isolates carrying blaOXA-1, a plasmid from one isolate
carrying blaTEM, and a plasmid from one isolate carrying both
blaTEM and blaOXA-1. The restriction profiles of three of these
four plasmids showed 60% to 85% similarities to each other
and up to 60% similarity to those of phylotype A isolates (Fig.
2 and 3). However, Southern hybridization analysis showed
that the plasmid fragments containing blaCTX-M-15 were all
different in size from each other and from those of phylotype
A isolates. The profile of a single blaCTX-M-15-carrying plasmid
from a phylotype B2 isolate (Ec9) was very similar to that of
pC15-1a, previously reported from Canada (5). However, the
blaCTX-M-15 probe hybridized to ca. 23-kb and 4.5-kb plasmid
fragments, whereas the Canadian plasmids hybridized to ca.
23-kb and 12-kb plasmid fragments (Fig. 3). The other three
plasmids in phylotype B2 isolates (Ec15, Ec23, and Ec27) had
profiles similar to those of “cluster I” plasmids, reported in
isolates from multiple countries (Fig. 2) (11). Plasmid profiles
of phylotype A did not match with published plasmid profiles.
DISCUSSION
Prior to 2007, CTX-M-producing E. coli isolates were rarely
reported in the United States (7, 22). At our institution, TEM-
and SHV-type ESBLs were still predominant until late 2006,
when CTX-M-15-producing E. coli isolates were identified
(13). The number of clinical cases caused by CTX-M-produc-
ing E. coli then increased steadily after around August 2007.
The proportion of CTX-M production among ESBL-produc-
ing E. coli isolates in our study was high (57 of 70 isolates
[81%]). This result was consistent with the findings of a na-
tionwide survey, which detected CTX-M-type ESBLs in 83%
of ESBL-producing E. coli isolates (7). A recent study con-
ducted in two hospitals in Philadelphia also reported that a
significant portion (48%) of their cephalosporin-resistant E.
coli isolates produced CTX-M-type ESBLs (24). Our findings
add to the growing evidence that CTX-M-type ESBLs, in par-
ticular CTX-M-15, are becoming the predominant ESBLs in E.
coli strains in the United States.
Our study identified several noteworthy features of the mo-
lecular epidemiology of CTX-M-producing E. coli isolates at
TABLE 2. Resistance genes and phylotypes of ESBL-producing
E. coli isolates
-Lactamase gene No. (%) ofisolates
No. of isolates of phylotype:
A B1 B2 D
CTX-M 57 (81) 26 0 18 13
CTX-M-15 46 (66) 25a 0 15b 6
CTX-M-2 1 (1) 0 0 0 1
CTX-M-9 group 10 (14) 1 0 3 6
CTX-M-9 1 (1) 0 0 0 1
CTX-M-14 8 (11) 1 0 3c 4
CTX-M-65 1 (1) 0 0 0 1d
SHV-5 or -7 10 (14) 1 1 5e 3
TEM-10 1 (1) 0 0 1 0
CMY-2 or -32 2 (3) 0 0 0 2
Total 70 27 1 24 18
a All isolates possessed blaOXA-1 and aac-6-Ib, and 19 isolates shared 75%
similarities based on PFGE.
b All 15 isolates were O25-ST131. The presence of blaTEM, blaOXA-1, and
aac-6-Ib differed among the isolates.
c All isolates were O25-ST131.
d This isolate also possessed blaCMY-2.
e Three isolates were O25-ST131.
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FIG. 1. Dendrogram based on PFGE profiles of 70 E. coli isolates. Ph, phylotype; A, pulsotype A; B, pulsotype B.
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our institution. First, two major clones of CTX-M-15-produc-
ing E. coli were identified. The first was a CTX-M-15-produc-
ing E. coli clone with the characteristics of the international
epidemic clone, i.e., phylotype B2, serotype O25:H4, and
ST131 (9, 11, 27, 38). Some variation in PFGE profiles was
observed for isolates within the ST131 clonal group. This phe-
nomenon has been reported previously (20, 27). The second
clone, which is unique to this study, was a CTX-M-15-produc-
ing E. coli clone belonging to phylotype A and ST410. A recent
study of CTX-M-15-producing E. coli isolates in the United
States reported that 45% of such isolates were ST131 (17). Our
study found a lower percentage of ST131 among our CTX-M-
15-producing E. coli isolates (33%). The predominant CTX-
M-15-producing clone at our institution was that in phylotype
B2 until late 2007. However, the phylotype A clone replaced
the phylotype B2 clone thereafter and continued to predomi-
nate until the end of the study period. Isolates in phylotype A,
along with those in phylotype B1, are conventionally consid-
ered commensals, less virulent than isolates in phylotypes B2
and D. The tendency of the CTX-M-15-producing phylotype A
clone to spread therefore mandates further investigation, in-
cluding detailed clinical analysis and determination of viru-
lence factors.
Second, in addition to the clonal spread of phylotype A
CTX-M-15-producing E. coli, which was demonstrated by both
PFGE and plasmid analysis, horizontal transfer of the blaCTX-M-
15-carrying plasmid appears to have occurred between phylo-
types A and D. While we cannot determine which phylotype
acquired this plasmid first, the fact that this plasmid is able to
maintain its stability regardless of different phylogenetic back-
grounds is intriguing. On the other hand, plasmid profiles of
phylotype B2 isolates were more variable. This is consistent
with the findings from Europe, Canada, and Asia documenting
the genetic variability of blaCTX-M-15-carrying plasmids in this
phylotype (11). It is worth noting that the fingerprints of the
blaCTX-M-15-carrying plasmids from phylotype B2 were clonally
related (60% similarity) to that of the plasmid representing
the CTX-M-15-producing phylotype A clone, suggesting the
possibility of common ancestry of these plasmids across the
phylotypes.
We tried to identify the location of blaCTX-M-15 in the rest of
the phylotype B2 isolates, whose plasmids were not transferred
by conjugation and transformation using several approaches.
Southern hybridization analysis using a blaCTX-M-15 probe and
a PFGE gel showed that blaCTX-M-15 was located on fragments
larger than 200 kb, indicating that these fragments were either
on very large plasmids or on the chromosome. Southern hy-
bridization analysis of plasmids from these isolates was nega-
tive for blaCTX-M-15 (data not shown). Finally, S1 nuclease
analysis revealed the presence of large plasmids (50 kb) in
these isolates, none of which hybridized with the blaCTX-M-15
probe (data not shown) (16). These results suggested that
blaCTX-M-15 was likely located on the chromosome for these
isolates (11, 15).
Third, while the majority of ST131 isolates in our study
produced CTX-M-15 (n  15), we also observed ST131 for
E. coli isolates producing CTX-M-14 (n  3) and SHV-5 or
-7 (n  3). A recent study from Japan showed an association
of serotype O25 with ST73 in addition to ST131 (36). In
contrast to other studies, all of these ST131 isolates in this
Japanese study produced enzymes of the CTX-M-2 and
CTX-M-9 groups. ST131 isolates without blaCTX-M-15 have
also been isolated from healthy humans in France and have
been found among virulent E. coli isolates in the United
States (3, 21). Thus, it is possible that ST131 strains are
particularly adept at acquiring plasmids that carry various
resistance determinants, not limited to blaCTX-M-15.
In summary, we characterized the emergence of two pre-
dominant clones of E. coli producing CTX-M-15 at our insti-
tution: one that constitutes part of the worldwide epidemic and
FIG. 2. Dendrogram of plasmids carrying blaCTX-M. Ph, phylotypes.
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one that has not been reported previously and thus appears to
have emerged locally. Our findings further demonstrate the
versatility of CTX-M-15 and the plasmids encoding this ESBL.
Detailed molecular typing of plasmids and genomes of isolates
from various locations will help better define the epidemiology
of CTX-M-15-producing E. coli in the Unites States. In addi-
tion, further work is required to examine the virulence of
CTX-M-15-producing isolates in various phylotypes and to
evaluate the clinical impact of acquisition of these isolates.
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